Asta Medica, Aktiengesellschaft

Asta Pharma Aktiengesellschaft

Heinz Ulrich

Helmut Hettche

Klaus Wessel

Lester Packer

Harald Borbe

Carl-Heinrich Weischer

Hans Bisswanger

Amira Klip

Jurgen Engel

Hermann-August Henrich

Frank Conrad

Wolfgang Geise

Bernd Nickel

J&uuml;rgen Engel

Stefan Szelenyi

Erich F Elstner

Gabriela Pergande

Werner E Muller

Michael Schwarz

Gabriele Pergande

Neville Osborne

Use of R-(&plus;)-&agr;-lipoic acid, R-(&minus;)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae

Pharmaceutical compositions and processes for their preparation containing R-&agr;-lipoic acid or S-&agr;-lipoic acid or pharmaceutically acceptable salts thereof. The pharmaceutical compositions have a cytoprotective activity and are suitable for combatting pain and inflammation.

Pharmaceutical compositions containing R-&agr;-lipoic acid or S-&agr;-lipoic acid as active ingredient

The invention relates to the use of flupirtine or its salts for the production of a medicament for the prophylaxis and therapy of disorders which accompany an unphysiologically high cell death rate. Of particular importance here is the treatment of organ disorders with cell-destroying processes, such as myocardial infarct, shock kidney, shock lung, senile macular degeneration or traumas as a result of mechanical, thermal, radiation or toxic influences.

Use of flupirtine for the prophylaxis and therapy of disorders which are

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance. These drugs mentioned can also be used advantageously in combination with other antidiabetic drugs, particularly with insulin, and/or other additives or stabilizers or adjuvants, such as vitamin E, vitamin C, NADH, NADPH and ubiquinone. The invention furthermore relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, as well as their salts, esters and amides for the preparation of drugs for the treatment of diseases with limited function of or a lowered content of the glucose transporters.

Use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid and

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance.

A method of improving the properties of liquid stored or cryogenically stored erythrocytes using D,L-.alpha.-lipoic acid and/or enantiomers or derivatives thereof. Treatment with these substances results in improved oxygen release capacity (2,3-DPG), viscoelasticity and erythrocyte aggregability, and increased resistance to membrane peroxidation during storage and damage by the freeze/thaw process.

Method of increasing viability of stored erythrocytes by addition of

Pharmaceutical compositions and processes for their preparation containing R-.alpha.-lipoic acid or S-.alpha.-lipoic acid or pharmaceutically acceptable salts thereof. The pharmaceutical compositions have a cytoprotective activity and are suitable for combatting pain and inflammation.

Pharmaceutical composition containing R-.alpha.-lipoic acid or

Primary and secondary neuroprotective effect of flupirtine in

Use of R-(+)-.alpha.-lipoic acid, R-(-)dihydrolipoic acid and

Dihydrolipoic acid as an ophthalmological agent to suppress intolerance

The invention relates to the use of DL-(+/-)-.alpha. lipoic acid, D-(+)-.alpha.-lipoic acid, L-(-)-.alpha.-lipoic acid in reduced or oxidized form or of the metabolites and salts, esters, amides thereof for the preparation of medicines for the treatment of disorders caused by changes or disturbances in the rheological properties of the blood such as blood viscosity, erythrocyte flexibility and the aggregation of erythrocytes, in particular for the treatment of microangiopathy with disturbed microcirculation. It can also be used in the treatment of diabetics and of dialysis patients for protection of the erythrocytes, in central and peripheral circulatory disturbances and in tinnitus and hearing loss.

Use of DL-(+/-)-.alpha.-lipoic acid, D-(+)-.alpha.-lipoic acid,

A pharmaceutical composition containing alpha-lipoic acid, dihydrolipoic acid, metabolites of alpha-lipoic acid (inter alia bisnortetralipoic acid and tetranorlipoic acid), optical isomers R- and S- forms of alpha-lipoic acid in oxidized and reduced form together with a vitamin, especially vitamins A, B1, B2, B6, B12, C and E and their pharmaceutically acceptable salts. The compositions are useful for producing analgesic, anti-inflammatory, antidiabetic, cytoprotective, anti-ulcer, antinecrotic, neuroprotective, detoxifying, anti-ischemic, liver function regulating, anti-allergic, immune-stimulating and antioncogenic effects.

Combination medications containing alpha-lipoic acid and related

Pharmaceutical compositions and their preparation which contain dihydrolipoic acid or its pharmaceutically acceptable salts as active substance. The pharmaceutical compositions have a cytoprotective effect and are suitable for combatting pain and inflammatory disorders.

Growing community of inventors

Niedernberg, Germany

Heinz Ulrich